Clinical trial NCT05523128: The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.
Official title: A Non-randomized, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of a Single Intravenous Infusion of ZS802 in Hemophilia A Subjects With Endogenous FVIII ≤2%.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Hemophilia A
Keywords: Hemophilia A
Gene therapy
Adeno-associated virus
Lead sponsor: Institute of Hematology & Blood Diseases Hospital, China
Sponsor class: OTHER
First posted: 2022-08-31
Enrollment: 6
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Hemophilia A patients
Primary purpose: TREATMENT

Brief summary: A non-randomized, open-label, dose-escalation study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS802 in hemophilia A subjects with endogenous FVIII ≤2%.

Detailed description: This study will seek to determine the safety, tolerability, kinetics and efficacy of a single IV infusion of ZS802.

Hemophilia A is a genetic bleeding disorder resulting in the lack of ability to produce blood-clotting factor VIII (FVIII). Individuals with hemophilia A suffer repeated bleeding events, which can cause chronic joint disease and sometimes leads to death due to the inability for blood to clot efficiently. The current treatment is intravenous infusion of FVIII protein products, either prophylactically or in response to bleeding. ZS802 is an adeno-associated viral (AAV) vector designed to drive expression of the human factor VIII (hFVIII) transgene and raise circulating levels of endogenous FVIII.

6 patients will be enrolled sequentially every 3 weeks or more between cohorts and administered with single infusion of ZS802. Dose escalation may occur based on the safety and FVIII activity on steady state. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg. Subjects will provide informed consent and then undergo screening assessments up to 6-8weeks prior administration of ZS802. All subjects will undergo 52 weeks safety and efficacy observation.

Eligibility criteria: Inclusion Criteria:

1. Male ≥18 years and ≤65years of age;
2. Confirmed diagnosis of hemophilia A, and endogenous FVIII ≤2%:

   1. \<1% (\<1 IU/dL) endogenous FVIII activity levels as historically documented by a certified laboratory or screening data results; OR
   2. 1%-2% (1-2 IU/dL) endogenous FVIII activity levels and \>10 bleeding events per year (in the last 52 weeks prior to screening); OR
   3. 1%-2% (1-2 IU/dL) endogenous FVIII activity levels and on prophylaxis;
3. Have had ≥150 prior exposure days (EDs) to any recombinant and/or plasma-derived FVIII protein products.
4. Agree to use reliable barrier contraception and prohibition of sperm donation until 52 weeks after the administration of ZS802.
5. Subjects voluntarily participate and are fully informed, fully understand the research and can comply with the requirements of the research protocol, are willing to complete the research as planned, and voluntarily cooperate with the provision of biological samples for testing.

Exclusion Criteria:

1. Hypersensitivity to any component of the study drug (including immunosuppressants) or a condition that can not use.
2. Inability to tolerate immunosuppressants or steroid drugs.
3. Have no measurable FVIII inhibitor as assessed by laboratory; or documented no prior history of FVIII inhibitor.
4. Who have a history or are currently suffering from any of the following serious clinical diseases:

   1. History of malignancy or current presence of any malignancy;
   2. Have active autoimmune disease;
   3. Severe heart disease, including angina pectoris, myocardial infarction, heart failure, clinically significant congenital heart disease, heart valve disease, arrhythmia and atrioventricular block, etc.;
   4. Have underlying liver disease or history of liver disease (such as portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy or hepatic fibrosis);
   5. Have active hepatitis B infection (HBsAg positive or HBV-DNA positive) or active hepatitis C infection (HCVAb positive), or are currently receiving hepatitis B or hepatitis C antiviral therapy;
   6. Have history of chronic infection or other chronic disease that the Investigator considers to constitute an unacceptable risk;
   7. Diabetes mellitus that is poorly controlled after drug treatment;
   8. Uncontrolled hypertension or hypotension;
5. laboratory values:

   1. Hemoglobin\<110g/L;
   2. Platelets\<100×10\^9/L;
   3. AST, ALT, alkaline phosphatase\>2×ULN;
   4. Total bilirubin\>1.5×ULN;
   5. Creatinine\>ULN;
   6. Albumin\<LLN;
   7. HIV antibody positive or Treponema pallidum antibody positive.
6. Have AAV5 capsid neutralizing antibody titers \>1:5.
7. Those who have received clinical trials of gene therapy before screening, or have used FVIII clinical trial drugs within 1 month, or participated in other drug/device clinical trials within 3 months, or plan to participate in other clinical trials during this study.
8. Those who have planned surgery within 52 weeks after the infusion.
9. Those who donated or lost more than 400 mL of blood within 3 months before screening.
10. Those with epilepsy, history of mental illness (such as schizophrenia, depression, mania or anxiety) or obvious mental disorder, incapacitated or incapacitated by other reasons.
11. Patients with a history of drug abuse or alcoholism.
12. Investigators believe that subjects have poor compliance or are expected to be less likely to complete follow-up.
13. There are clinically significant diseases or other reasons that the researcher and/or collaborators consider unsuitable to participate in this researcher.

Primary outcomes:
measure: Incidence of adverse events
timeFrame: Baseline up to Week 52
measure: Number of participants with clinically significant change from baseline in vital signs
timeFrame: Baseline up to Week 52
measure: Number of participants with clinically significant change from baseline in physical examination findings
timeFrame: Baseline up to Week 52
measure: Number of participants with clinical laboratory abnormalities
timeFrame: Baseline up to Week 52
Secondary outcomes:
measure: Vector-derived FVIII:C Activity
timeFrame: Baseline up to Week 52
measure: Vector-derived FVIII antigen levels
timeFrame: Baseline up to Week 52
measure: Vector shedding of ZS802
timeFrame: Baseline up to Week 52
measure: Antibody against AAV capsid protein
timeFrame: Baseline up to Week 52
Other outcomes:
measure: Annualized bleeding rate changes from baseline
timeFrame: Baseline up to Week 52
measure: Annualized FVIII consumption changes from baseline
timeFrame: Baseline up to Week 52
measure: Number of target joints
timeFrame: Baseline up to Week 52
Locations:
city: Tianjin
country: China
facility: Institute of Hematology & Blood Diseases Hospital
Study officials:
affiliation: Institute of Hematology & Blood Diseases Hospital, China
name: Lei Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References: